Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Glycoconjugates are major constituents of mammalian cells that are formed via covalent
conjugation of carbohydrates to other biomolecules like proteins and lipids and often …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …

Drug conjugates are conjugates comprising a tumor-homing carrier tethered to a cytotoxic
agent via a linker that are designed to deliver an ultra-toxic payload directly to the target …

The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …